# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration...
Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab ...
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, c...
https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997Even as the Covid wave in F...
- Reuters
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clini...